Cantor starts InflaRx at Overweight ahead of upcoming Phase 3 data

As previously reported, Cantor Fitzgerald initiated coverage of InflaRx (IFRX) with an Overweight rating and $10 price target Upcoming Phase 3 interim data due in May for the company’s lead asset vilobelimab in pyoderma gangrenosum is a “potentially major, unappreciated catalyst,” the analyst tells investors. The risk/reward into this blinded interim analysis has a “very large positive skew,” the analyst argues.